Application for production of bortezomib for injection of six chemical drugs in Haizheng Pharmaceutical Co., Ltd. was accepted

Bortezomib for injection, a 6-class chemical drug declared by Haizheng pharmaceutical, has been accepted According to the inquiry, the company has previously applied for bortezomib as the drug substance of the preparation in early November 2013 At present, only the original bortezomib for injection is on sale in China, and no domestic enterprise has produced the product Bortezomib for injection is the world's first cancer drug targeting at proteasome, which is mainly used for the treatment of multiple myeloma (mm) The product was first approved for listing in the world in May 2003 The original research drug product was named Wanke, which was produced by BVL company in the United States and sold by Xi'an Janssen, a Chinese subsidiary of Johnson & Johnson in China According to IMS survey data, Vanke ranked seventh among the world's best-selling anti-tumor drugs in 2010, with annual sales reaching US $1.7 billion, up 19% year on year According to CFDA, in addition to Haizheng pharmaceutical, there are 7 domestic enterprises applying for the production approval of the product, among which Jiangsu aosaikang has made rapid progress, and the company expects that the product will be listed in 2015 Haizheng pharmaceutical is a leading API manufacturer in China and one of the largest production bases of antibiotics and anti-tumor drugs in China At present, the company is in the transition period from API to international high-end preparations.